A Two-Part Single Center, Randomized, Sequential, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTP-543 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Ruxolitinib deuterated (Primary)
- Indications Alopecia areata
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Concert Pharmaceuticals
- 04 Mar 2017 Results of this trial were presented in a poster session at the American Academy of Dermatology Annual Meeting, according to a Concert Phamaceuticals media release.
- 04 Mar 2017 Results published in a Concert Phamaceuticals media release.
- 14 Dec 2016 According to a Concert Phamaceuticals media release, status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History